Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid

Woburn, MA, July 21, 2026 (GLOBE NEWSWIRE) — Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today announced plans to commercialize D-PLEX100  upon approval in the United States and Canada for the prevention of abdominal colorectal surgical site infections (“SSIs”) in partnership with PolyPid Ltd. (“PolyPid”), an innovative biopharmaceutical company dedicated to improving patient outcomes […]